Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
Zonghai LI
Zonghai LI

Chairman & CEO


 CARsgen Therapeutics, Ltd

Zonghai Li M.D., Ph.D., is dedicated himself to develop innovative treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become the most widely used unnatural peptide in antitumor study now. He is the inventor of many new technologies such as Hpd3cell, a new phage display technology; FR806, a new safety switch for T cell therapy; Run-CAR technology to increase the antitumor activities of chimeric antigen receptor (CAR) T cells. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide.